(Circulation. 1996;94:2083-2089.)
© 1996 American Heart Association, Inc.
Articles |
Effects of Integrelin, a Platelet Glycoprotein IIb/IIIa Receptor Antagonist, in Unstable Angina
A Randomized Multicenter Trial
the Division of Cardiology, Johns Hopkins Medical Institutions, Baltimore, Md; Cleveland (Ohio) Clinic Foundation; Duke University Medical Center, Durham, NC; Mother Frances Hospital, Tyler, Tex; University of Texas, Houston; St Frances Hospital, Roslyn, NY; Texas Heart Institute, Houston; Riverside Methodist Hospital, Columbus, Ohio; St Agnes Hospital, Baltimore, Md; Moffitt Hospital, University of California, San Francisco; Lynchburg (Va) General Hospital; Franklin Square Hospital, Baltimore, Md; Alameda (Calif) Hospital; St Vincent's Hospital, Erie, Pa; Biometric Research Institute, Arlington, Va; and COR Therapeutics, San Francisco, Calif.
Background Although aspirin is beneficial in patients with unstable angina, it is a relatively weak inhibitor of platelet aggregation. The effect of Integrelin, which inhibits the platelet fibrinogen receptor glycoprotein (GP) IIb/IIIa, on the frequency and duration of Holter ischemia was evaluated in 227 patients with unstable angina.
Methods and Results Patients received intravenous heparin and standard anti-ischemic therapy and were randomized to receive oral aspirin and placebo Integrelin; placebo aspirin and low-dose Integrelin, 45 µg/kg bolus followed by a 0.5-µg·kg-1·min-1 continuous infusion; or placebo aspirin and high-dose Integrelin, 90 µg/kg bolus followed by a 1.0-µg·kg-1·min-1 constant infusion. Study drug was continued for 24 to 72 hours, and Holter monitoring was performed. Patients randomized to high-dose Integrelin experienced 0.24±0.11 ischemic episodes (mean±SEM) on Holter lasting 8.41±5.29 minutes over 24 hours of study drug infusion. Patients randomized to aspirin experienced a greater number (1.0±0.33, P<.05) and longer duration (26.2±9.8 minutes, P=.01) of ischemic episodes than the high-dose Integrelin group. There was no evidence of rebound ischemia after withdrawal of study drug. In 46 patients, platelet aggregation was rapidly inhibited by Integrelin in a dose-dependent fashion. The number of clinical events was small, and there were no bleeding differences in the three treatment arms.
Conclusions Intravenous Integrelin is well tolerated, is a potent reversible inhibitor of platelet aggregation, and added to full-dose heparin reduces the number and duration of Holter ischemic events in patients with unstable angina compared with aspirin.
Key Words: integrins • angina • platelets • ischemia
This article has been cited by other articles:
 |
|
 |
|
  C. Bode Introduction Eur. Heart J. Suppl., August 1, 2007; 9(suppl_D): D1 - D2. [Full Text] [PDF]
|
|
|
|
 |
|
 S. Patel, M. Patel, I. Din, C. V. R. Reddy, and J. Kassotis Profound Thrombocytopenia Associated with Tirofiban: Case Report and Review of Literature Angiology, May 1, 2005; 56(3): 351 - 355. [Abstract] [PDF]
|
|
|
|
 |
|
 S. G. Goodman, D. Fitchett, P. W. Armstrong, M. Tan, A. Langer, and for the Integrilin and Enoxaparin Randomized Asses Randomized Evaluation of the Safety and Efficacy of Enoxaparin Versus Unfractionated Heparin in High-Risk Patients With Non-ST-Segment Elevation Acute Coronary Syndromes Receiving the Glycoprotein IIb/IIIa Inhibitor Eptifibatide Circulation, January 21, 2003; 107(2): 238 - 244. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Marzilli, G. Sambuceti, R. Testa, and S. Fedele Platelet glycoprotein IIb/IIIa receptor blockade and coronary resistance in unstable angina J. Am. Coll. Cardiol., December 18, 2002; 40(12): 2102 - 2109. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. E. Tardiff, L. K. Jennings, R. A. Harrington, D. Gretler, R. F. Potthoff, D. A. Vorchheimer, P. R. Eisenberg, A. M. Lincoff, M. Labinaz, D. M. Joseph, et al. Pharmacodynamics and Pharmacokinetics of Eptifibatide in Patients With Acute Coronary Syndromes: Prospective Analysis From PURSUIT Circulation, July 24, 2001; 104(4): 399 - 405. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Butenas, K. M. Cawthern, C. van't Veer, M. E. DiLorenzo, J. B. Lock, and K. G. Mann Antiplatelet agents in tissue factor-induced blood coagulation Blood, April 15, 2001; 97(8): 2314 - 2322. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. G. Goodman, A. Barr, A. Sobtchouk, M. Cohen, G. J. Fromell, L. Laperriere, C. Hill, A. Langer, and for the Canadian Efficacy and Safety of Subcutaneo Low molecular weight heparin decreases rebound ischemia in unstable angina or non-Q-wave myocardial infarction: the Canadian ESSENCE ST segment monitoring substudy J. Am. Coll. Cardiol., November 1, 2000; 36(5): 1507 - 1513. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y.-T. Shen, R. T. Wiedmann, J. J. Lynch Jr, and R. J. Gould Platelet Glycoprotein IIb/IIIa Receptor Inhibitor Preserves Coronary Flow Reserve During Progressive Coronary Arteriostenosis in Swine Arterioscler. Thromb. Vasc. Biol., October 1, 2000; 20(10): 2309 - 2315. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. L. Bhatt and E. J. Topol Current Role of Platelet Glycoprotein IIb/IIIa Inhibitors in Acute Coronary Syndromes JAMA, September 27, 2000; 284(12): 1549 - 1558. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. H. Awtry and J. Loscalzo Aspirin Circulation, March 14, 2000; 101(10): 1206 - 1218. [Full Text] [PDF]
|
|
|
|
|
|
M. Verstraete Synthetic Inhibitors of Platelet Glycoprotein IIb/IIIa in Clinical Development Circulation, February 15, 2000; 101 (6): e76 - e80. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Brodison, R. Katira, R. S More, and A. Chauhan Current practice: Antiplatelet use in interventional cardiology Postgrad. Med. J., February 1, 2000; 76(892): 70 - 79. [Abstract] [Full Text]
|
|
|
|
 |
|
 D. J Schneider, D. J Taatjes, and B. E Sobel Paradoxical inhibition of fibrinogen binding and potentiation of {alpha}-granule release by specific types of inhibitors of glycoprotein IIb-IIIa Cardiovasc Res, January 14, 2000; 45(2): 437 - 446. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Satre, L. Holmvang, G.S. Wagner, B. Lindahl, and L. Wallentin Reduction of myocardial damage by prolonged treatment with subcutaneous low molecular weight heparin in unstable coronary artery disease Eur. Heart J., May 1, 1999; 20(9): 645 - 652. [Abstract] [PDF]
|
|
|
|
|
|
B. van der Loo and J. F. Martin A Role for Changes in Platelet Production in the Cause of Acute Coronary Syndromes Arterioscler. Thromb. Vasc. Biol., March 1, 1999; 19(3): 672 - 679. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Nurden, C. Poujol, C. Durrieu-Jais, J. Winckler, R. Combrie, L. Macchi, C. Bihour, C. Wagner, R. Jordan, and A. T. Nurden Labeling of the Internal Pool of GP IIb-IIIa in Platelets by c7E3 Fab Fragments (abciximab): Flow and Endocytic Mechanisms Contribute to the Transport Blood, March 1, 1999; 93(5): 1622 - 1633. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Pabla, A. S. Weyrich, D. A. Dixon, P. F. Bray, T. M. McIntyre, S. M. Prescott, and G. A. Zimmerman Integrin-dependent Control of Translation: Engagement of Integrin alpha IIbbeta 3 Regulates Synthesis of Proteins in Activated Human Platelets J. Cell Biol., January 11, 1999; 144(1): 175 - 184. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. F. Kong, R. M. Califf, D. P. Miller, D. J. Moliterno, H. D. White, R. A. Harrington, J. E. Tcheng, A. M. Lincoff, V. Hasselblad, and E. J. Topol Clinical Outcomes of Therapeutic Agents That Block the Platelet Glycoprotein IIb/IIIa Integrin in Ischemic Heart Disease Circulation, December 22, 1998; 98(25): 2829 - 2835. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R.F. Storey, R.G. Wilcox, and S. Heptinstall Differential Effects of Glycoprotein IIb/IIIa Antagonists on Platelet Microaggregate and Macroaggregate Formation and Effect of Anticoagulant on Antagonist Potency : Implications for Assay Methodology and Comparison of Different Antagonists Circulation, October 20, 1998; 98(16): 1616 - 1621. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. J. Kereiakes, N. S. Kleiman, J. J. Ferguson, A. R. Z. Masud, T. M. Broderick, C. W. Abbottsmith, J. P. Runyon, L. C. Anderson, R. J. Anders, R. J. Dreiling, et al. Pharmacodynamic Efficacy, Clinical Safety, and Outcomes After Prolonged Platelet Glycoprotein IIb/IIIa Receptor Blockade With Oral Xemilofiban : Results of a Multicenter, Placebo-Controlled, Randomized Trial Circulation, September 29, 1998; 98(13): 1268 - 1278. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 The PURSUIT Trial Investigators Inhibition of Platelet Glycoprotein IIb/IIIa with Eptifibatide in Patients with Acute Coronary Syndromes N. Engl. J. Med., August 13, 1998; 339(7): 436 - 443. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
The Platelet Receptor Inhibition in Ischemic Syndr Inhibition of the Platelet Glycoprotein IIb/IIIa Receptor with Tirofiban in Unstable Angina and Non-Q-Wave Myocardial Infarction N. Engl. J. Med., May 21, 1998; 338(21): 1488 - 1497. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. C. Wu, E. A. Zerhouni, R. M. Judd, C. H. Lugo-Olivieri, L. A. Barouch, S. P. Schulman, R. S. Blumenthal, and J. A. C. Lima Prognostic Significance of Microvascular Obstruction by Magnetic Resonance Imaging in Patients With Acute Myocardial Infarction Circulation, March 3, 1998; 97(8): 765 - 772. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. P. Cannon, C. H. McCabe, S. Borzak, T. D. Henry, M. D. Tischler, H. S. Mueller, R. Feldman, S. T. Palmeri, K. Ault, S. A. Hamilton, et al. Randomized Trial of an Oral Platelet Glycoprotein IIb/IIIa Antagonist, Sibrafiban, in Patients After an Acute Coronary Syndrome : Results of the TIMI 12 Trial Circulation, February 3, 1998; 97(4): 340 - 349. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Altman Controversies in Antithrombotic Therapy in Cardiovascular Diseases Clinical and Applied Thrombosis/Hemostasis, January 1, 1998; 4(1): 11 - 24. [Abstract] [PDF]
|
|